Epkinly is a bispecific CD20-directed CD3 T-cell engager used for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after a couple of or more lines of systemic therapy.
Note: Epkinly is approved on behalf of patient response data. A study is ongoing to confirm the clinical benefit of this medication. It is not known if this therapeutic medicine is safe and promising in children.
Recommended Dosage: The recommended regimen for Epkinly is subcutaneous (SC) administration in 28-day cycles until disease progression or unacceptable adverse events. Epkinly’s recommended dose typically comprises step-up dosing in cycle 1 (0.16 mg on day 1, 0.8 mg on day 8, and 48 mg on days 15 and 22) followed by fixed dosing of 48 mg weekly during cycles 2 & 3, every other week during cycles 4 through 9, and then every 4 weeks on day 1 of subsequent cycles.